Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E F Smit

Showing results (101-110 of 185) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)N Van Zandwijk, E F Smit, G W Kramer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patientsC G Ferreira, P van der Valk, S W Span, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced diseaseB Besse, A Adjei, P Baas, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 24, 2013
Semiautomated volumetric response evaluation as an imaging biomarker in superior sulcus tumorsC G Vos, M Dahele, J R van Sörnsen de Koste, et al.
European Journal of Clinical Nutrition|January 12, 2012
Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCTB S van der Meij, J A E Langius, M D Spreeuwenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1991
Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic studyE F Smit, P H Willemse, D T Sleijfer, et al.
EJNMMI Research|August 18, 2020
Quantification of [<sup>18</sup>F]afatinib using PET/CT in NSCLC patients: a feasibility studyE A van de Stadt, M Yaqub, A A Lammertsma, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2004
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development GroupG Giaccone, E F Smit, M de Jonge, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2003
The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatmentC J Hoekstra, S G Stroobants, O S Hoekstra, et al.
Clinical Radiology|January 28, 2010
Re: Sarcoid-like reaction to malignancy on whole-body integrated 18F-FDG PET/CT: prevalence and disease patternA A M van der Veldt, E F I Comans, F B J M Thunnissen, et al.
Pageof 19

Showing results (101-110 of 185) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)N Van Zandwijk, E F Smit, G W Kramer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patientsC G Ferreira, P van der Valk, S W Span, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced diseaseB Besse, A Adjei, P Baas, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 24, 2013
Semiautomated volumetric response evaluation as an imaging biomarker in superior sulcus tumorsC G Vos, M Dahele, J R van Sörnsen de Koste, et al.
European Journal of Clinical Nutrition|January 12, 2012
Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCTB S van der Meij, J A E Langius, M D Spreeuwenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1991
Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic studyE F Smit, P H Willemse, D T Sleijfer, et al.
EJNMMI Research|August 18, 2020
Quantification of [<sup>18</sup>F]afatinib using PET/CT in NSCLC patients: a feasibility studyE A van de Stadt, M Yaqub, A A Lammertsma, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2004
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development GroupG Giaccone, E F Smit, M de Jonge, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2003
The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatmentC J Hoekstra, S G Stroobants, O S Hoekstra, et al.
Clinical Radiology|January 28, 2010
Re: Sarcoid-like reaction to malignancy on whole-body integrated 18F-FDG PET/CT: prevalence and disease patternA A M van der Veldt, E F I Comans, F B J M Thunnissen, et al.
Pageof 19